Horizon Pharma PLC (NASDAQ:HZNP) – Equities researchers at Jefferies Group lifted their Q4 2017 earnings estimates for Horizon Pharma PLC in a research note issued to investors on Tuesday. Jefferies Group analyst D. Steinberg now expects that the biopharmaceutical company will post earnings of $0.22 per share for the quarter, up from their prior estimate of $0.17. Jefferies Group has a “Buy” rating and a $21.00 price target on the stock. Jefferies Group also issued estimates for Horizon Pharma PLC’s FY2018 earnings at $1.04 EPS, FY2019 earnings at $1.17 EPS and FY2020 earnings at $1.43 EPS.

Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. Horizon Pharma PLC had a positive return on equity of 20.22% and a negative net margin of 45.28%. The firm had revenue of $271.60 million for the quarter, compared to analysts’ expectations of $259.74 million. During the same period in the prior year, the firm posted $0.70 earnings per share. The firm’s quarterly revenue was up 30.1% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: “Q4 2017 EPS Estimates for Horizon Pharma PLC Raised by Jefferies Group (HZNP)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/11/q4-2017-eps-estimates-for-horizon-pharma-plc-raised-by-jefferies-group-hznp.html.

HZNP has been the topic of a number of other reports. Piper Jaffray Companies set a $17.00 price target on Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Mizuho reissued a “hold” rating and issued a $12.00 target price (up previously from $9.00) on shares of Horizon Pharma PLC in a report on Monday, August 28th. Zacks Investment Research lowered Horizon Pharma PLC from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. ValuEngine lowered Horizon Pharma PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, UBS AG set a $16.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $18.42.

Horizon Pharma PLC (HZNP) opened at $13.57 on Thursday. Horizon Pharma PLC has a twelve month low of $9.45 and a twelve month high of $21.98. The company has a market capitalization of $2,171.49, a P/E ratio of 9.60, a P/E/G ratio of 1.12 and a beta of 1.32. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.46.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Prudential Financial Inc. lifted its holdings in shares of Horizon Pharma PLC by 2.6% during the 1st quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 420 shares in the last quarter. Sheaff Brock Investment Advisors LLC lifted its holdings in Horizon Pharma PLC by 5.0% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 500 shares in the last quarter. Amalgamated Bank raised its stake in shares of Horizon Pharma PLC by 4.8% in the 2nd quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 943 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Horizon Pharma PLC by 16.3% in the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 1,378 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Horizon Pharma PLC by 1.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock valued at $1,495,000 after purchasing an additional 1,379 shares in the last quarter. 82.56% of the stock is owned by institutional investors.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Earnings History and Estimates for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.